Search results
Showing 46 to 60 of 8216 results
Cladribine for treating relapsing–remitting multiple sclerosis (TA616)
Evidence-based recommendations on cladribine (Mavenclad) for relapsing–remitting multiple sclerosis in adults.
Our board has 2 sub-committees: the audit and risk assurance committee and the remuneration committee . Audit and risk assurance committee The audit
On this page, you'll find all our position statements relating to technology appraisals. Biosimilar technologies: NICE position statement Biosimilar
1. Provisional appraisal topics chosen The NICE topic selection programme produces a list of provisional appraisal topics. 2. Stakeholders identified
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration (TA155)
Evidence-based recommendations on ranibizumab (Lucentis) and pegaptanib (Macugen) for treating wet age-related macular degeneration in adults.
Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)
Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia in adults.
Evidence-based recommendations on ranibizumab (Lucentis) for treating visual impairment caused by macular oedema secondary to retinal vein occlusion in adults.
Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Our diagnostics assessment recommendations are prepared by an independent advisory committee called the diagnostics advisory committee (DAC). Standing
Advises NICE on the formulation of its guidance on the safety and efficacy of interventional procedures.
NICE transparency of spend
Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes (IPG787)
Evidence-based recommendations on endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetes. This involves using heat to destroy the lining of the duodenum to encourage a new lining to grow.
View recommendations for IPG787Show all sections
Image-guided percutaneous laser ablation for primary and secondary liver tumours (IPG788)
Evidence-based recommendations on image-guided percutaneous laser ablation for primary and secondary liver tumours. This involves heating up liver tissue to destroy tumours.
View recommendations for IPG788Show all sections
We want people from all walks of life to contribute to our work and share their experience, expertise and passion. We are committed to providing a...
Our staff really enjoy working with us, thanks to our great package of rewards and benefits. We offer flexible ways of working, which means a better